Cell And Gene Therapy Clinical Milestones Highlight Reimbursement Challenges
This article was originally published in Scrip
The Stem Cell Meeting on the Mesa began on Oct. 7 in San Diego just a few days after Spark Therapeutics posted positive Phase III results that could support the first-ever US FDA approval of a gene therapy, but the achievement and the conference highlighted a still-unsolved challenge for regenerative medicines: How will health care systems pay for curative, one-time treatments?
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.